Next Article in Journal
NUTM1-Rearranged Neoplasms—A Heterogeneous Group of Primitive Tumors with Expanding Spectrum of Histology and Molecular Alterations—An Updated Review
Next Article in Special Issue
Renin-Angiotensin System Single Nucleotide Polymorphisms Are Associated with Bladder Cancer Risk
Previous Article in Journal
Surgical Oncology: Multidisciplinarity to Improve Cancer Treatment and Outcomes
Previous Article in Special Issue
DNA Repair Gene Polymorphisms and Susceptibility to Urothelial Carcinoma in a Southeastern European Population
Article

ERCC1 19007 Polymorphism in Greek Patients with Advanced Urothelial Cancer Treated with Platinum-Based Chemotherapy: Effect of the Changing Treatment Paradigm: A Cohort Study by the Hellenic GU Cancer Group

1
2nd Propaedeutic Department of Internal Medicine, National & Kapodistrian University of Athens, ATTIKON University Hospital, 12462 Athens, Greece
2
Hellenic Genito-Urinary Cancer Group, 89 Evrou St, 11527 Athens, Greece
3
Department of Clinical Therapeutics, National & Kapodistrian University of Athens, ALEXANDRA Hospital, 11528 Athens, Greece
4
Department of Urology, General Hospital of Athens “G. Gennimatas”, 11527 Athens, Greece
5
3rd Department of Internal Medicine, General Hospital of Athens “G. Gennimatas”, 11527 Athens, Greece
6
2nd Department of Surgery, Aretaieion Academic Hospital, School of Medicine, National & Kapodistrian University of Athens, 15772 Athens, Greece
7
2nd Department of Urology, Sismanoglio Hospital, National & Kapodistrian University of Athens, 15772 Athens, Greece
8
1st University Urology Clinic, Laiko Hospital, University of Athens, 11527 Athens, Greece
9
Department of Urology, Korgialenio Benakio Hellenic Red Cross Hospital, 11526 Athens, Greece
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2021, 28(6), 4474-4484; https://doi.org/10.3390/curroncol28060380
Received: 14 September 2021 / Revised: 20 October 2021 / Accepted: 1 November 2021 / Published: 5 November 2021
We previously showed that ERCC1 19007 C>T polymorphism was associated with cancer-specific survival (CSS) after platinum-based chemotherapy in patients with advanced urothelial cancer (aUC). We aimed to confirm this association in a different cohort of patients. Genotyping of the 19007C>T polymorphism was carried out by polymerase chain reaction (PCR) amplification and restriction fragment length polymorphism (RFLP) in 98 aUC patients, treated with platinum-based chemotherapy. Median age of the patients was 68.8, 13.3% of them were female, 90.8% had ECOG PS of 0 or 1, and 48% received cisplatin-based chemotherapy. In addition to chemotherapy, 32.7% of the patients received immunotherapy, and 19.4% vinflunine. Eighty-one patients (82.7%) were carriers of the 19007T polymorphic allele: 46 (46.9%) were heterozygotes, and 35 (35.7%) were homozygotes. The ERCC1 polymorphism was not associated with CSS, progression-free (PFS), or overall (OS) survival in the total population. Nevertheless, there was a significant interaction between the prognostic significance of ERCC1 polymorphism and the use of modern immunotherapy: the T allele was associated with worse outcome in patients who received chemotherapy only, while this association was lost in patients who received both chemotherapy and immune checkpoint inhibitors. Our study suggests that novel therapies may influence the significance of ERCC1 polymorphism in patients with aUC. Its determination may be useful in the changing treatment landscape of the disease. View Full-Text
Keywords: ERCC1; bladder cancer; chemotherapy; immunotherapy; vinflunine ERCC1; bladder cancer; chemotherapy; immunotherapy; vinflunine
Show Figures

Figure 1

MDPI and ACS Style

Bamias, A.; Koutsoukos, K.; Gavalas, N.; Zakopoulou, R.; Tzannis, K.; Dedes, N.; Boulouta, A.; Fragkoulis, C.; Kostouros, E.; Dellis, A.; Mitsogiannis, I.; Adamakis, I.; Anastasiou, I.; Skolarikos, A.; Papatsoris, A.; Stravodimos, K.; Ferakis, N.; Pagoni, S.; Ntoumas, K.; Mitropoulos, D.; Deliveliotis, C.; Constantinides, C.A.; Dimopoulos, M.A. ERCC1 19007 Polymorphism in Greek Patients with Advanced Urothelial Cancer Treated with Platinum-Based Chemotherapy: Effect of the Changing Treatment Paradigm: A Cohort Study by the Hellenic GU Cancer Group. Curr. Oncol. 2021, 28, 4474-4484. https://doi.org/10.3390/curroncol28060380

AMA Style

Bamias A, Koutsoukos K, Gavalas N, Zakopoulou R, Tzannis K, Dedes N, Boulouta A, Fragkoulis C, Kostouros E, Dellis A, Mitsogiannis I, Adamakis I, Anastasiou I, Skolarikos A, Papatsoris A, Stravodimos K, Ferakis N, Pagoni S, Ntoumas K, Mitropoulos D, Deliveliotis C, Constantinides CA, Dimopoulos MA. ERCC1 19007 Polymorphism in Greek Patients with Advanced Urothelial Cancer Treated with Platinum-Based Chemotherapy: Effect of the Changing Treatment Paradigm: A Cohort Study by the Hellenic GU Cancer Group. Current Oncology. 2021; 28(6):4474-4484. https://doi.org/10.3390/curroncol28060380

Chicago/Turabian Style

Bamias, Aristotelis, Konstantinos Koutsoukos, Nikos Gavalas, Roubini Zakopoulou, Kimon Tzannis, Nikos Dedes, Anna Boulouta, Charalampos Fragkoulis, Eythymios Kostouros, Athanasios Dellis, Iraklis Mitsogiannis, Ioannis Adamakis, Ioannis Anastasiou, Andreas Skolarikos, Athanasios Papatsoris, Konstantinos Stravodimos, Nikolaos Ferakis, Stamatina Pagoni, Konstantinos Ntoumas, Dionysios Mitropoulos, Charalambos Deliveliotis, Constantinos A. Constantinides, and Meletios A. Dimopoulos. 2021. "ERCC1 19007 Polymorphism in Greek Patients with Advanced Urothelial Cancer Treated with Platinum-Based Chemotherapy: Effect of the Changing Treatment Paradigm: A Cohort Study by the Hellenic GU Cancer Group" Current Oncology 28, no. 6: 4474-4484. https://doi.org/10.3390/curroncol28060380

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop